The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21.20 - Manufacture of pharmaceutical preparations
248 jobs Number of planned job losses
22 jobs Number of planned job creations
Announcement Date
20 March 2018
Employment effect (start)
1 June 2018
Foreseen end date
31 December 2018
Description
In the framework of a global restructuring announced in December 2017 that will lead to cut 14,000 jobs worldwide, the Israelian group has announced a reorganisation of its French activities that will lead to cut 248 positions (on a total of 578) in its sales department and at its headquarter at Paris-La-Défense. The group will launch a voluntary departure plan and, will implement forced dismissals to complete the job cuts. On the total of 248 job cuts, 61 will result from the cancelation of vacant positions and 60 will consist of internal redemployment. The group will also hire 22 employees related to digitalisation. The group justifies this plan with drugs pricing, high costs due to regulatory and environmental requirements, and a delay in the expected penetration of Teva generic medicines in the country.
Sources
20 March 2018: Le Monde
Citation
Eurofound (2018), Teva, Internal restructuring in France, factsheet number 93695, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/93695.